On November 8, 2022, Eiger BioPharmaceuticals, Inc. was sued for violations of the federal securities laws in the United States District Court for the Northern District of California on behalf of investors who purchased or otherwise acquired Eiger securities between March 10, 2021 and October 4, 2022.
We use cookies to improve your overall web experience. By using our website, you consent to the use of cookies in accordance with our Privacy Policy.